Peter Sazani Selected Research

Morpholinos

1/2017	Effects of systemic multiexon skipping with peptide-conjugated morpholinos in the heart of a dog model of Duchenne muscular dystrophy.
1/2016	Toxicological Characterization of Exon Skipping Phosphorodiamidate Morpholino Oligomers (PMOs) in Non-human Primates.
11/2013	Eteplirsen for the treatment of Duchenne muscular dystrophy.
5/2011	Chemical and mechanistic toxicology evaluation of exon skipping phosphorodiamidate morpholino oligomers in mdx mice.
5/2011	Repeat-dose toxicology evaluation in cynomolgus monkeys of AVI-4658, a phosphorodiamidate morpholino oligomer (PMO) drug for the treatment of duchenne muscular dystrophy.
3/2010	Safety pharmacology and genotoxicity evaluation of AVI-4658.
2/2010	Long-term improvement in mdx cardiomyopathy after therapy with peptide-conjugated morpholino oligomers.
9/2009	Peptide-morpholino conjugate: a promising therapeutic for Duchenne muscular dystrophy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Peter Sazani Research Topics

Disease

6	Duchenne Muscular Dystrophy (Muscular Dystrophy, Becker) 01/2017 - 09/2009
3	Body Weight (Weight, Body) 01/2016 - 05/2011
2	Muscular Dystrophies (Muscular Dystrophy) 01/2017 - 02/2010
2	Neoplasms (Cancer) 01/2013 - 02/2009
2	Experimental Arthritis 07/2008 - 07/2008
2	Hepatitis 07/2008 - 07/2008
2	Inflammation (Inflammations) 07/2008 - 07/2008
2	Arthritis (Polyarthritis) 07/2008 - 07/2008
2	Rheumatoid Arthritis 07/2008 - 07/2008
1	Inborn Genetic Diseases (Disease, Hereditary) 01/2017
1	Kidney Cortex Necrosis 01/2016
1	Neuromuscular Diseases (Neuromuscular Disease) 01/2016
1	Infections 07/2015
1	Dog Diseases (Disease, Canine) 03/2010
1	Cardiomyopathies (Cardiomyopathy) 02/2010
1	Cardiomegaly (Heart Hypertrophy) 02/2010
1	Breast Neoplasms (Breast Cancer) 02/2009

Drug/Important Bio-Agent (IBA)

8	MorpholinosIBA 01/2017 - 09/2009
6	DystrophinIBA 01/2017 - 02/2010
4	Proteins (Proteins, Gene)FDA Link 01/2017 - 07/2008
4	eteplirsenIBA 01/2016 - 05/2011
4	OligonucleotidesIBA 01/2013 - 07/2008
3	Peptides (Polypeptides)IBA 01/2017 - 09/2009
2	Arginine (L-Arginine)FDA Link 01/2017 - 02/2010
2	Cell-Penetrating PeptidesIBA 01/2017 - 02/2010
2	Pharmaceutical PreparationsIBA 05/2011 - 02/2009
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 07/2008 - 07/2008
2	Etanercept (Enbrel)FDA Link 07/2008 - 07/2008
1	Urea (Carbamide)FDA LinkGeneric 01/2016
1	CreatinineIBA 01/2016
1	NitrogenIBA 01/2016
1	Hormones (Hormone)IBA 01/2016
1	Complement System Proteins (Complement)IBA 01/2016
1	AVI-7288IBA 07/2015
1	salicylhydroxamic acid (SHAM)IBA 02/2010
1	Trastuzumab (Herceptin)FDA Link 02/2009
1	RNA Precursors (Precursor, mRNA)IBA 02/2009
1	herstatinIBA 02/2009

Therapy/Procedure

3	Therapeutics 01/2013 - 02/2009
1	Aftercare (After-Treatment) 02/2010
1	Secondary Prevention 02/2010